MIRO - Miromatrix Medical Inc. Stock Price, Fair Value and News

3.39USD Market Closed

Market Summary

USD3.39

Market Closed

MIRO Stock Price

View Fullscreen

MIRO RSI Chart

MIRO Valuation

Market Cap

93.0M

Price/Earnings (Trailing)

-3.39

Price/Sales (Trailing)

97.49

Price/Free Cashflow

-3.82

MIRO Price/Sales (Trailing)

MIRO Profitability

Return on Equity

-176.36%

Return on Assets

-117.03%

Free Cashflow Yield

-26.15%

MIRO Fundamentals

MIRO Revenue

Revenue (TTM)

953.5K

Rev. Growth (Yr)

-9.83%

Rev. Growth (Qtr)

31.22%

MIRO Earnings

Earnings (TTM)

-27.4M

Earnings Growth (Yr)

15.4%

Earnings Growth (Qtr)

1.17%

Breaking Down MIRO Revenue

Last 30 days

2.4%

Last 90 days

151.1%

Trailing 12 Months

17.7%

How does MIRO drawdown profile look like?

MIRO Financial Health

Current Ratio

3.46

Debt/Equity

0.02

Debt/Cashflow

-62.98

MIRO Investor Care

Shares Dilution (1Y)

31.17%

Diluted EPS (TTM)

-1.15

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	33.7K	28.5K	31.1K	953.5K
2021	64.7K	100.9K	119.1K	33.1K
2020	0	0	0	46.5K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Miromatrix Medical Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 13, 2023	burke william p. mr.	back to issuer	-	-	-67,413	-
Dec 13, 2023	buckman paul	back to issuer	-	-	-54,201	-
Dec 13, 2023	douglas james michael	back to issuer	-	-	-20,000	chief financial officer
Dec 13, 2023	maag peter	back to issuer	-	-	-58,368	-
Dec 13, 2023	erb john l	back to issuer	-	-	-54,201	-
Dec 13, 2023	heine lisa wipperman	back to issuer	-	-	-67,413	-
Dec 13, 2023	ross jeffrey james	back to issuer	-	-	-87,500	chief executive officer
Dec 12, 2023	heine lisa wipperman	sold	-	-	-66,943	-
Dec 12, 2023	buckman paul	sold	-	-	-52,593	-
Dec 12, 2023	erb john l	sold	-	-	-56,260	-

Which funds bought or sold MIRO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-862,698	-	-%
Feb 16, 2024	HARBOUR INVESTMENTS, INC.	sold off	-100	-3,609	-	-%
Feb 14, 2024	STATE STREET CORP	sold off	-100	-36,321	-	-%
Feb 14, 2024	First Light Asset Management, LLC	sold off	-100	-2,985,060	-	-%
Feb 14, 2024	Gagnon Advisors, LLC	sold off	-100	-729,349	-	-%
Feb 14, 2024	G2 Investment Partners Management LLC	sold off	-100	-221,027	-	-%
Feb 14, 2024	RTW INVESTMENTS, LP	sold off	-100	-583,241	-	-%
Feb 14, 2024	GAGNON SECURITIES LLC	sold off	-100	-1,910,440	-	-%
Feb 13, 2024	ENVESTNET ASSET MANAGEMENT INC	sold off	-100	-62,927	-	-%
Feb 13, 2024	MORGAN STANLEY	sold off	-100	-1,310	-	-%

Are Funds Buying or Selling MIRO?

Are funds buying MIRO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MIRO

No. of Funds

Unveiling Miromatrix Medical Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	lytton laurence w	0%	0	SC 13G/A
Feb 14, 2024	davita inc.	0%	0	SC 13G/A
Dec 22, 2023	united therapeutics corp	00.0%	1	SC 13D
Dec 12, 2023	gagnon neil	3.6%	998,022	SC 13G/A
Dec 07, 2023	first light asset management, llc	9.45%	2,592,022	SC 13G
May 11, 2023	lytton laurence w	5.1%	1,380,367	SC 13G
Feb 06, 2023	gagnon neil	4.4%	922,885	SC 13G/A
Feb 16, 2022	gagnon neil	3.4%	684,984	SC 13G
Feb 14, 2022	baxter international inc	10.3%	2,083,333	SC 13G
Feb 11, 2022	davita inc.	9.8%	1,980,091	SC 13G

Recent SEC filings of Miromatrix Medical Inc.

View All Filings

Date Filed	Form Type	Document
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Miromatrix Medical Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.9B	6.8B	23.52%	-6.94%	-8.03	7	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	0.99%	-25.83%	-58.02	9.62	75.20%	68.82%
BMRN	15.7B	2.5B	-4.94%	-13.58%	76.24	6.34	13.74%	186.89%
INCY	12.1B	3.8B	-2.80%	-18.78%	16.19	3.2	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-16.72%	-43.78%	-10.82	14.42	425.83%	18.94%
BBIO	5.2B	107.9M	-4.79%	106.15%	-9.53	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	1.74%	5.10%	-14.81	13.09	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.74%	-39.00%	-10.2	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.55%	-20.97%	-45.79	3.86	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-4.91%	-11.58%	24.31	4.36	85.90%	-14.05%
NVAX	687.2M	983.7M	8.15%	-35.14%	-1.26	0.7	-50.36%	17.16%
CRBP	408.0M	881.7K	0.99%	345.87%	-9.15	466.16	-77.61%	-5.33%
INO	282.8M	4.9M	-1.94%	21.49%	-2.09	58.11	-54.97%	51.71%
IBIO	6.9M	2.1M	-32.65%	86.79%	-0.25	2.14	-13.45%	66.37%

Miromatrix Medical Inc. News

Latest updates

Miromatrix Medical Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2021Q1	2020Q4	2020Q3	2020Q2
Revenue	31.2%	11,176	8,517	469,436	930,355	12,395	3,952	6,768	8,000	9,819	9,139	6,108	93,985	52,416	10,846	9,394
Gross Profit	2.3%	-113,824	-116,483	-117,019	805,355	-112,605	-121,048	-118,232	-117,000	-115,181	-115,861	-118,892	47,708	-	-114,154	-115,606
Operating Expenses	-0.8%	6,521,264	6,571,929	7,982,010	7,985,405	7,643,679	8,113,420	7,075,396	5,347,531	5,093,435	3,456,722	2,600,367	-	-	2,470,077	2,755,137
S&GA Expenses	5.2%	2,143,421	2,037,682	2,600,235	2,206,121	2,052,731	2,188,460	2,272,557	1,806,623	1,487,654	786,322	562,874	-	-	460,105	605,147
R&D Expenses	-3.2%	3,506,054	3,621,224	4,392,118	4,733,953	4,574,534	4,988,233	4,006,666	3,057,173	3,349,898	2,480,887	1,868,001	-	-	1,870,039	2,078,903
EBITDA Margin	-	-	-	-	-	-	-495	-426	-442	-364	-355	-268	-	-268	-268	-285
Interest Expenses	800.2%	7,913	879	3,173	5,763	8,447	1,845	4,221	4,454	9,231	1,996	6,772	-	-	-	-
EBT Margin	-	-	-	-	-	-	-518	-439	-447	-367	-358	-269	-	-269	-269	-290
Net Income	1.2%	-6,453,691	-6,530,420	-7,480,152	-6,946,005	-7,628,054	-8,182,189	-7,203,749	-5,475,999	-5,057,581	-3,702,834	-434,342	-223,633	-1,088,031	-2,992,225	-3,273,079
Net Income Margin	4.1%	-28.75	-29.98	-31.71	-31.42	-915	-908	-635	-443	-79.11	-53.99	-57.23	-117	-221	-	-
Free Cashflow	9.8%	-4,571,504	-5,067,630	-8,616,406	-6,055,229	-6,836,374	-6,362,939	-7,428,039	-6,598,210	-2,820,204	-3,213,688	-2,177,127	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet											(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-17.7%	23,421	28,451	34,242	34,763	40,608	47,654	53,957	60,929	64,226	67,122	5,254
Current Assets	-21.4%	17,192	21,881	27,348	27,311	32,835	33,959	46,144	55,337	62,547	66,770	4,690
Cash Equivalents	33.8%	6,116	4,572	13,620	5,208	5,538	12,593	44,685	53,612	62,088	66,526	4,444
Net PPE	-5.8%	4,711	4,999	5,271	5,546	5,816	5,792	5,992	5,592	1,679	351	325
Liabilities	14.1%	7,879	6,903	6,442	8,656	7,865	7,643	6,500	6,803	4,959	3,713	9,627
Current Liabilities	27.7%	4,966	3,887	3,325	4,946	4,058	3,736	2,489	4,564	3,558	2,458	8,164
Long Term Debt	0%	386	386	386	386	386	386	386	386	479	462	929
LT Debt, Current	-	-	-	-	-	15.00	38.00	61.00	334	-	-	-
LT Debt, Non Current	0%	386	386	386	386	386	386	386	386	-	-	-
Shareholder's Equity	-27.9%	15,542	21,548	27,800	26,107	32,743	40,011	47,457	54,126	59,267	63,408	-
Retained Earnings	-5.5%	-124,476	-118,000	-111,492	-104,011	-97,065	-89,437	-81,255	-74,051	-68,575	-63,518	-59,381
Additional Paid-In Capital	0.3%	140,018	139,570	139,292	130,119	129,808	129,449	128,713	128,178	127,843	126,926	8,347
Shares Outstanding	0.4%	27,419	27,311	27,240	20,944	20,664	20,615	20,478	20,386	20,145	2,914	2,186

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	9.8%	-4,571	-5,067	-8,616	-6,055	-6,836	-6,362	-7,428	-6,598	-2,820	-3,213	-2,177	-	-	-
Share Based Compensation	15.8%	323	279	332	298	253	266	334	238	145	106	133	-	-	-
Cashflow From Investing	259.6%	6,000	-3,759	7,984	5,793	-124	-26,144	-613	-1,935	-1,361	-80.18	1,994	-	-	-
Cashflow From Financing	152.5%	116	-220	9,044	-67.49	-94.68	416	-85.17	58.00	-256	65,556	2.00	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MIRO Income Statement

2023-09-30

Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
Statements of Operations - USD ($)	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Statements of Operations
Licensing revenue	$ 11,176	$ 12,395	$ 27,674	$ 23,115
Revenue from Contract with Customer, Product and Service	us-gaap:LicenseMember	us-gaap:LicenseMember	us-gaap:LicenseMember	us-gaap:LicenseMember
Cost of goods sold	$ 125,000	$ 125,000	$ 375,000	$ 375,000
Cost, Product and Service	us-gaap:LicenseMember	us-gaap:LicenseMember	us-gaap:LicenseMember	us-gaap:LicenseMember
Gross loss	$ (113,824)	$ (112,605)	$ (347,326)	$ (351,885)
Operating expenses:
Research and development	3,506,054	4,574,534	11,519,395	13,569,434
Regulatory and clinical	455,313	381,903	1,259,077	1,156,535
Quality	416,476	634,511	1,515,394	1,592,778
General and administration	2,143,421	2,052,731	6,781,337	6,513,748
Total operating expenses	6,521,264	7,643,679	21,075,203	22,832,495
Operating loss	(6,635,088)	(7,756,284)	(21,422,529)	(23,184,380)
Other income (expense)
Interest income	196,681	143,555	464,820	205,403
Interest expense	(15,284)	(15,325)	(33,697)	(35,015)
Employee retention credit receivable			(527,143)
Total other income	181,397	128,230	958,266	170,388
Net loss	$ (6,453,691)	$ (7,628,054)	$ (20,464,263)	$ (23,013,992)
Net loss per share, basic (in dollar per share)	$ (0.24)	$ (0.37)	$ (0.80)	$ (1.11)
Net loss per share, diluted (in dollar per share)	$ (0.24)	$ (0.37)	$ (0.80)	$ (1.11)
Weighted average shares used in computing net loss per share, basic (in shares)	27,313,881	20,895,513	25,714,215	20,664,494
Weighted average shares used in computing net loss per share, diluted (in shares)	27,313,881	20,895,513	25,714,215	20,664,494

MIRO Balance Sheet

2023-09-30

Balance Sheets - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 6,116,084	$ 5,208,005
Restricted cash	800,100	800,100
Short-term investments	9,945,715	19,989,489
Employee retention credit receivable	70,000
Receivable from Reprise Biomedical, Inc.	11,176	930,355
Interest receivable	9,433	107,861
Prepaid expenses and other current assets	239,922	274,952
Total current assets	17,192,430	27,310,762
Deferred offering costs		232,899
Right of use asset	1,517,956	1,673,575
Property and equipment, net	4,710,763	5,545,694
Total assets	23,421,149	34,762,930
Current liabilities:
Current portion of deferred royalties	862,609	979,167
Accounts payable	1,048,364	1,584,929
Current portion of financing lease obligations	17,281	44,157
Current portion of lease liability	413,650	389,649
Accrued expenses	2,624,031	1,948,376
Total current liabilities	4,965,935	4,946,278
Deferred royalties, net		491,733
Long-term debt	385,997	385,997
Financing lease obligations, net		11,689
Lease liability, net	2,406,066	2,720,781
Accrued interest	120,780	99,048
Total liabilities	7,878,778	8,655,526
Commitments and contingencies
Shareholders' equity:
Common stock, par value $0.00001; 190,000,000 shares authorized; 27,419,228 issued and outstanding as of September 30, 2023 and 20,944,109 issued and outstanding as of December 31, 2022	274	209
Additional paid-in capital	140,018,271	130,119,106
Accumulated deficit	(124,476,174)	(104,011,911)
Total shareholders' equity	15,542,371	26,107,404
Total liabilities and shareholders' equity	$ 23,421,149	$ 34,762,930

About Miromatrix Medical Inc.

Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. The company's proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. It has collaborations with Baxter, CareDx, The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota.

CEO	Dr. Jeffrey James Ross Ph.D.
WEBSITE	miromatrix.com
INDUSTRY	Biotechnology
EMPLOYEES	76

Miromatrix Medical Inc. Frequently Asked Questions

What is the ticker symbol for Miromatrix Medical Inc.? What does MIRO stand for in stocks?

MIRO is the stock ticker symbol of Miromatrix Medical Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Miromatrix Medical Inc. (MIRO)?

As of Fri Dec 22 2023, market cap of Miromatrix Medical Inc. is 92.95 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MIRO stock?

You can check MIRO's fair value in chart for subscribers.

What is the fair value of MIRO stock?

You can check MIRO's fair value in chart for subscribers. The fair value of Miromatrix Medical Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Miromatrix Medical Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MIRO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Miromatrix Medical Inc. a good stock to buy?

The fair value guage provides a quick view whether MIRO is over valued or under valued. Whether Miromatrix Medical Inc. is cheap or expensive depends on the assumptions which impact Miromatrix Medical Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MIRO.

What is Miromatrix Medical Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 22 2023, MIRO's PE ratio (Price to Earnings) is -3.39 and Price to Sales (PS) ratio is 97.49. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MIRO PE ratio will change depending on the future growth rate expectations of investors.